04Recent Activity
Iterion Therapeutics reported first clinical validation of Tegavivint as a targeted therapy for Wnt-driven advanced HCC in an oral presentation at the 2026 ASCO Annual Meeting.
JUN 3, 2026
Iterion Therapeutics is a clinical-stage, biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation, focusing on developing therapeutics for cancer, particularly targeting Wnt-driven tumors
Iterion Therapeutics is a clinical-stage, biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation, focusing on developing therapeutics for cancer, particularly targeting Wnt-driven tumors.